Symbicort Turbuhaler 60MD: Advanced Asthma & COPD Control
| Product dosage: 100 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $39.56 | $39.56 (0%) | 🛒 Add to cart |
| 2 | $31.39 | $79.12 $62.78 (21%) | 🛒 Add to cart |
| 3 | $27.52
Best per inhaler | $118.68 $82.56 (30%) | 🛒 Add to cart |
| Product dosage: 200 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $43.00 | $43.00 (0%) | 🛒 Add to cart |
| 2 | $39.13 | $86.00 $78.26 (9%) | 🛒 Add to cart |
| 3 | $35.26
Best per inhaler | $129.00 $105.78 (18%) | 🛒 Add to cart |
| Product dosage: 400 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $47.30 | $47.30 (0%) | 🛒 Add to cart |
| 2 | $43.00 | $94.60 $86.00 (9%) | 🛒 Add to cart |
| 3 | $37.84
Best per inhaler | $141.90 $113.52 (20%) | 🛒 Add to cart |
Synonyms | |||
Symbicort Turbuhaler 60MD is a combination maintenance inhaler designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It integrates an inhaled corticosteroid (budesonide) and a long-acting beta2-agonist (formoterol) in a single, easy-to-use dry powder device. This formulation provides both anti-inflammatory and bronchodilatory effects, targeting the underlying pathophysiology of obstructive airway diseases. Clinically proven to improve lung function and reduce exacerbation frequency, it is a cornerstone therapy in modern respiratory care.
Features
- Contains budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per inhalation
- Delivers 60 metered doses per inhaler device
- Utilizes a multi-dose dry powder Turbuhaler delivery system
- Does not require shaking or coordination of actuation with inhalation
- Dose counter indicates remaining inhalations
- Breath-actuated mechanism for efficient drug deposition
Benefits
- Provides dual-action therapy by combining anti-inflammatory and bronchodilator effects in a single device
- Significantly improves lung function (FEV1) and peak expiratory flow rates
- Reduces the frequency and severity of asthma and COPD exacerbations
- Enhances symptom control, leading to improved quality of life and physical activity tolerance
- Offers convenient twice-daily dosing, supporting adherence to maintenance therapy
- Minimizes the need for rescue medication use through sustained bronchodilation
Common use
Symbicort Turbuhaler 60MD is indicated for the regular maintenance treatment of asthma in adults and adolescents (12 years and older) where use of a combination product is appropriate. It is also approved for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. It is not intended for the relief of acute bronchospasm.
Dosage and direction
For asthma: The recommended dose is 1-2 inhalations twice daily. The maximum recommended dose is 4 inhalations twice daily. For COPD: The recommended dose is 2 inhalations twice daily. Patients should rinse their mouth with water after inhalation to reduce the risk of oropharyngeal candidiasis. The Turbuhaler should be held upright during loading and patients should inhale deeply and forcefully through the mouthpiece. The dose counter will advance with each successful administration.
Precautions
Patients should be advised that Symbicort is not a rescue medication and should not be used to treat acute symptoms. Systemic effects of corticosteroids may occur, particularly at high doses over prolonged periods, including adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataracts, and glaucoma. Patients should be monitored for increased bronchial hyperreactivity. Paradoxical bronchospasm may occur—if this happens, treatment should be discontinued immediately. Caution is advised in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, or severe cardiovascular disorders.
Contraindications
Hypersensitivity to budesonide, formoterol, or any excipients (which include lactose). Should not be used for the treatment of acute asthma attacks or status asthmaticus. Not recommended in patients with known or suspected quinidine hypersensitivity. Contraindicated in patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmias.
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include oral candidiasis, dysphonia, headache, tremor, palpitations, throat irritation, and cough. Uncommon reactions (≥1/1,000 to <1/100) may include tachycardia, muscle cramps, anxiety, nausea, dizziness, sleep disturbances, and skin rash. Rare but serious side effects include angioedema, anaphylactic reactions, bronchospasm, cardiac arrhythmias, hyperglycaemia, hypokalaemia, and psychiatric effects including depression and behavioural disturbances. Long-term use of high doses may lead to systemic corticosteroid effects.
Drug interaction
Beta-blockers (including eye drops) may antagonise the bronchodilatory effect and increase risk of bronchospasm. Concomitant use with other beta-adrenergic drugs may potentiate sympathetic effects. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase budesonide plasma levels. Hypokalaemia may be potentiated by xanthine derivatives, steroids, diuretics, and hypoxia. Concomitant use with monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of formoterol. QT-prolonging agents may increase the risk of ventricular arrhythmias.
Missed dose
Patients should be instructed to take the next dose at the usual time. They should not take a double dose to make up for a forgotten one. Maintaining regular dosing is important for optimal disease control, but occasional missed doses are unlikely to cause significant clinical deterioration.
Overdose
Overdosage may lead to excessive beta-adrenergic stimulation and/or signs of systemic corticosteroid excess. Symptoms may include tachycardia, arrhythmias, tremor, headache, muscle cramps, dry mouth, nausea, dizziness, fatigue, malaise, hypokalaemia, hyperglycaemia, and metabolic acidosis. Cardiac arrest may occur. Supportive and symptomatic treatment is indicated. Consider cardiac monitoring and correction of electrolyte abnormalities. Dialysis is not appropriate.
Storage
Store in a dry place at room temperature (below 30°C). Keep the device in the moisture-protective foil until first use. After opening, the inhaler must be used within 3 months. The Turbuhaler should be kept clean and dry. The dose counter indicates when the inhaler is empty (shows zero). Do not expose to temperatures above 50°C. Keep out of sight and reach of children.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product description. Dosage and indications may vary by jurisdiction—always refer to local prescribing information.
Reviews
Clinical trials and real-world evidence consistently demonstrate Symbicort Turbuhaler’s efficacy in improving lung function and reducing exacerbation rates. In the SMART study, Symbicort maintenance and reliever therapy significantly reduced severe exacerbations compared with fixed-dose ICS/LABA plus SABA. Patients report improved symptom control and quality of life. Healthcare professionals appreciate its dual mechanism, dosing convenience, and reliable delivery system. Some users note the importance of proper inhalation technique for optimal drug delivery. Long-term safety profile is well-established with appropriate monitoring.